Xcout IntelHumacyte, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Humacyte, Inc. among biotech companies — ranked by similarity to what Humacyte, Inc. actually does, not by market-cap band.
Subscribe to see Humacyte, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Humacyte, Inc.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Humacyte, Inc. at a glance
Humacyte, Inc. is a biotech company headquartered in Durham, United States, founded in 2004. It is publicly listed (HUMA) with a market capitalisation of $131.9M. Xcout tracks 30 named people at Humacyte, Inc., including Dale A. Sander (Chief Financial Officer, Chief Corporate Development Officer & Treasurer).
Humacyte, Inc. leadership
- Dale A. SanderChief Financial Officer, Chief Corporate Development Officer & Treasurer
- Dale SanderChief Corporate Development Officer, Chief Financial Officer & Treasurer
- Shamik J. ParikhChief Medical Officer
- Heather ConnellyChief Quality & Regulatory Officer
- Jim MercadanteChief Commercial Officer
- Lisa MolyneuxChief Strategy Officer
24 more named people on record for Humacyte, Inc., with roles, board committees and tenure — see the full roster →
Humacyte, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $150M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Humacyte, Inc. competitors
Ranked by semantic similarity — how close each company is to Humacyte, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Frontier Bio develops engineered human tissues and vascular grafts to address cardiovascular disease and eliminate the need for organ donors and animal testing. The company provides tissue-engineered blood vessels for vascular grafts and commercializes human-based tissue models and services for preclinical testing.
Similar biotech company
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Biotechnology
Precise Bio, Inc. is a clinical-stage regenerative medicine company that grows live organs for transplant using 3D bio-printing technology.
Similar biotech company
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Similar biotech company
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Life Sciences
BMI OrganBank is a medical device and biotechnology company developing next-generation organ and tissue transplant solutions.
Biotechnology
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Biotechnology
Truelastin Laboratories develops natural elastin biomaterials and product platforms for human health applications. The company serves the medical aesthetics and therapeutic sectors by creating tissue-engineered products and advanced drug delivery systems.
Biotechnology
CoreTissue BioEngineering Inc. is a biotechnology company headquartered in Yokohama, Japan, operating out of the Life Science Research Center. The company specializes in research, development, and regenerative medicine applications within the life sciences sector. It provides advanced biomedical engineering solutions from its Japanese laboratory headquarters.
Similar biotech company
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Biotechnology
Tiger BioSciences is a medical technology company that specializes in regenerative medicine, developing cellular, acellular, and matrix-like products for wound care and aesthetic treatments. The company also manages human tissue recovery programs to supply biological materials for clinical applications. It serves healthcare providers and medical professionals globally.
Biotechnology
Regenity Biosciences is a medical device supplier and biotechnology company headquartered in Paramus, New Jersey, specializing in regenerative medicine and collagen matrix products with nearly 30 years of history.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Humacyte, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Humacyte, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →